UPPSALA, Sweden, Oct. 27, 2005 (PRIMEZONE) -- Q-Med:
- Turnover during the period amounted to SEK 669.1 (585.5) million, an increase of 14 percent. - Operating income amounted to SEK 59.0 (369.8) million. Adjusted for revenues and expenses of a one-time nature, operating income amounted to SEK 69.3 (38.9) million. - Net income after tax amounted to SEK 46.8 (316.3) million. - Earnings per share for the period were SEK 1.89 (12.75). - The very positive development for all products within Hospital Healthcare continues: +53%. - The reorganization in Latin America is completed. Sales in Mexico are being resumed during the fourth quarter.
Q-Med is a rapidly growing and profitable biotechnology/medical device company that develops, produces and markets medical implants. All products are based on the company's patented NASHA technology - Non-Animal Stabilized Hyaluronic Acid. The products covered by the RESTYLANE trademark are used for the filling out of lips and facial wrinkles and for facial contouring and today account for the majority of sales. RESTYLANE is sold in over 70 countries and has been approved in the USA. DUROLANE, Q-Med's product for the treatment of osteoarthritis of the hip and knee joints, has been approved in Europe since May 2001. DEFLUX is a product which has been approved in Europe and the USA for the treatment of vesicoureteral reflux (a malformation of the urinary bladder) in children. ZUIDEX for the treatment of stress urinary incontinence in women has been sold in Europe since July 2002. Q-Med today has approximately 550 employees, with approximately 350 at the company's production facility and head office in Uppsala. The Q-Med share is listed on the O-list, Attract 40, of the Stockholm Stock Exchange.
This information was brought to you by Waymaker http://www.waymaker.net
The following files are available for download:
http://wpy.waymaker.net/client/waymaker1/WOLReleaseFile.aspx?id=145222&fn=wkr0001.pdf